The Guardian

Bill Gates on philanthropy, genetic engineering, and Steve Jobs The Verge By Adi Robertson on January 25, 2012 06:28 pm 0Comments Bill Gates may no longer work with Microsoft, but he's still trying to use technology to change the world. In an interview with Nightline, Gates discusses his work with The Bill & Melinda Gates ... Gates defends focus on high-tech agricultureFox News all 986 news articles »

Source:
http://news.google.com/news?q=genetic-engineering&output=rss

Manila Bulletin

Only God Can Take Life Manila Bulletin I'm reminded of the following story told in a Pro-Life gathering: US scientists have tremendously advanced in genetic engineering, decoding genes, making clones. Flushed from their fantastic achievements, they concluded that God had become irrelevant; ...

Source:
http://news.google.com/news?q=genetic-engineering&output=rss

Washington Times

CURL: The end of the GOP as we knew it Washington Times Genetic engineering. Artificial intelligence. Hypersonic transportation. Nanotechnology. Human cloning. Hydrogen-powered cars. We're even working on antigravity machines. So where are the candidates of the Grand Old Party? They're busy trying to be a ... and more »

Source:
http://news.google.com/news?q=genetic-engineering&output=rss

South Korea is playing a risky game as it has given the permission for using human eggs in cloning research despite a high level scandal in their country which involved one of their top scientists admitting to his involvement in doctored research work. Hwang Woo-suk was the scientist who had claimed that he had cloned human embryos and extracted stem cells from them but it was found out that all his claims were false. What raised eyes were when eggs required for research were donated by a female scientist in his team and this questioned the ethics of such practice. This shameful incident caused Hwang Woo-suk to resign from his post at the Seoul National University and is now facing trial for misappropriation of government funds. In order to get over the shameful act the government has again given a go ahead to use of human eggs in cloning but this time with an act of caution and under a new set of guidelines has asked that researchers should only use eggs which are to be destroyed after fertility treatments or from other legal ways and a prior license would have to be obtained from the government for undertaking research. It seems this time South Korea wants to take no chances. Via theage

Source:
http://www.biotechblog.org/rss.xml

Portfolio.com

Biotechnology Funding Hits 4-Year High as Startups Suffer BusinessWeek 20 (Bloomberg) -- Venture capital investment in biotechnology increased 22 percent last year, while the number of those receiving their first funding declined. Funding for medical-device and equipment companies also rose 20 percent, with first-time ... Start-ups saw big rise in funding during '11The Boston Globe Biotech Venture Funding Jumped in 2011International Business Times all 197 news articles »

Source:
http://news.google.com/news?q=biotechnology&output=rss

Hindu Business Line

Bio-security, an emerging challenge Hindu Business Line Freedom to research in biotechnology shouldn't be hampered, but the risks must be dealt with. Advancements in biotechnology can be used to alarmingly destructive effect. Recently, in September 2011, researchers in Rotterdam succeeded in modifying the ... Biotechnology Can Provide Foundation for a US Economy "Built To Last"MarketWatch (press release) 2012 BIO International Convention to Highlight Insights from Senior Biotech ...EON: Enhanced Online News (press release) all 20 news articles »

Source:
http://news.google.com/news?q=biotechnology&output=rss

ABC News

New lung cancer test predicts survival PhysOrg.com In the two largest clinical studies ever conducted on the molecular genetics of lung cancer, an international team led by scientists at the University of California, San Francisco (UCSF) has demonstrated that an available molecular test can predict the ... Molecular test more accurate in predicting lung cancer survivalTruthDive Gene test may aid early-stage lung cancer patientsSan Francisco Chronicle Genetics test could help treat cancer patientsabc7news.com French Tribune -Daily Gossip all 72 news articles »

Source:
http://news.google.com/news?q=molecular-genetics&output=rss

DigitalJournal.com

'Flesh-eating' USA300 MRSA strain spread by sneezes and coughs DigitalJournal.com Metro reports Professor Chris Thomas, professor of molecular genetics at the University of Birmingham, said: "If you're on a crowded tube or bus and you sneeze you can spread the bacteria. But your sneeze can also land on a metal surface and when ... Flesh-eating bug USA300 spread by sneezes and coughsMetro Flesh-Eating Strain Of MRSA Reaches UKHuffington Post UK all 12 news articles »

Source:
http://news.google.com/news?q=molecular-genetics&output=rss

PhysOrg.com

2012 Japan Prize honors cancer fighters, magnet man Network World This year's prize for Healthcare and Medical Technology went to American medical experts, Janet Rowley, MD, Blum-Riese Distinguished Service Professor of Medicine, Molecular Genetics & Cell Biology and Human Genetics of the University of Chicago; ... Rowley to receive Japan Prize for her role in the development of targeted ...EurekAlert (press release) Dr. Brian Druker honored with Japan PrizePhysOrg.com (press release) all 12 news articles »

Source:
http://news.google.com/news?q=molecular-genetics&output=rss

Scientist

More Research on Virus Mutations Published Occupational Health and Safety Graduate student Justin Meyer and Richard Lenski, Hannah Distinguished Professor of Microbiology and Molecular Genetics at Michigan State University, have published a new paper in the journal Science that adds to the current debate about research that ... How new viruses evolve potentially dangerous traitsTruthDive all 29 news articles »

Source:
http://news.google.com/news?q=molecular-genetics&output=rss

Health Newstrack

New lung cancer test could accurately guide treatment for people with lung cancer Health Newstrack by Anil Kumar In the two largest clinical studies ever conducted on the molecular genetics of lung cancer, an international team led by scientists at the University of California, San Francisco (UCSF) has demonstrated that an available molecular test ... Possible life-saving test for lung cancerABC7Chicago.com all 5 news articles »

Source:
http://news.google.com/news?q=molecular-genetics&output=rss

The Cancer Stem Cell Consortium (CSCC) is a partner in the 2012 Large-Scale Applied Research Project Competition of Genome Canada, in collaboration with the first phase of the Personalized Medicine Signature Initiative of the Canadian Institutes of Health Research (CIHR). Genome Canada is leading the research competition. An excerpt from Fact Sheet: The Potential of Personalized Medicine:

Funding of $67.5M will come from Genome Canada ($40 million), CIHR ($22.5 million) and the Cancer Stem Cell Consortium ($5 million). Projects will be funded for a maximum of four years. To qualify for funding, researchers must obtain matching funding that at is least equal to that provided through the competition, which will bring the total investment in this research area to close to $140 million. Matching funding is typically derived from provincial, academic, private sector or international sources.

Details about the competition are available here.

Press releases, dated January 31, 2012, about the federal government's support for personalized medicine, are available here and here.

Source:
http://cancerstemcellnews.blogspot.com/feeds/posts/default?alt=rss

Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss

The Center for Genetics and Society has filed a brief statement with the Institute of Medicine panel examining the performance of the California stem cell agency, expressing the hope that the inquiry will include "a broader range of sources."

Marcy Darnovsky, associate executive director of the Berkeley group, said that "a meaningful review by (the IOM) committee could make an important contribution to needed changes at the agency." Darnovsky's organization has followed the stem cell effort since its inception.

She noted that CIRM is "a public agency spending increasingly scarce public resources" and has raised the possibility of seeking another multibillion dollar bond measure from voters.

The IOM inquiry has finished half of its public process and is yet to hear an independent analysis of the stem cell agency, which is paying $700,000 for the study.

Earlier Darnovsky told the California Stem Cell Report that the Institute of Medicine has not contacted her organization for comments, although she has spoken with the public relations person for the IOM.

Here is the text of Darnovsky's statement sent to the IOM.

"The Center for Genetics and Society is a public interest organization working to ensure responsible uses and effective societal governance of human genetic and reproductive technologies.  We support embryonic stem cell research, but have been concerned for some years about a number of aspects of the field, and of the California Institute of Regenerative Medicine in particular.

"We have been closely following CIRM since the campaign for Proposition 71 that established it in 2004. We have attended numerous meetings of the agency’s governing board and Standards Working Group, worked with other public interest groups who share our concerns about CIRM, written frequently about CIRM in our publications, and been cited dozens of times in articles about CIRM in key state and national news outlets.

"In 2006, we published The California Stem Cell Program at One Year: A Progress Report, which assessed CIRM's performance to that date and offered recommendations. See http://www.geneticsandsociety.org/downloads/200601report.pdf

"In 2008, CGS policy analyst Jesse Reynolds gave invited testimony to the Little Hoover Commission’s hearing on CIRM. See http://www.geneticsandsociety.org/article.php?id=4386

"We are encouraged that the Institute of Medicine is undertaking an independent assessment of CIRM, though we hope that you will invite input from a broader range of sources than were represented at the meeting last month in San Francisco. With key questions about the future of CIRM unresolved, and its leadership contemplating a campaign for another bond measure.

"As I wrote in a recent commentary that expressed our disappointment with the roster of speakers at last month’s hearing,

"Ballot measure or no ballot measure, CIRM will continue to disperse the public money it controls – another billion and a half dollars. This is a public agency spending increasingly scarce public resources. It is funding a field of research in which we place great hopes for medical and scientific advances. These factors make it all the more crucial that CIRM follow the basics of good governance and public accountability, and eschew the hyperbole and exaggerated promises that have tainted stem cell research for so long.

"See  http://www.geneticsandsociety.org/article.php?id=6045

"Please let us know if we can be of help. We would be very glad to share our insights and recommendations."

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

The blue-ribbon panel examining the performance of the $3 billion California stem cell agency is midway through its public process and is yet to hear from a single independent witness during its open sessions.

The panel's report and recommendations are due this fall and are expected to have a major impact on the seven-year-old agency and its future.

So far, the IOM panel has heard only from employees or directors of the agency and persons representing institutions that have received $418 million in CIRM cash.

The panel of scientists and academics was put together by the prestigious Institute of Medicine under a $700,000 contract with the stem cell agency itself. At the 2010 meeting during which agency directors approved the contract, they expressed hope that the IOM panel's findings would bolster public support for another multibillion dollar bond measure for the agency, which expects to run out of funds for new grants in 2017.

Last week, the California Stem Cell Report asked the IOM about its plans to gather independent or critical information about the stem cell agency's performance. With only one more California public meeting scheduled, the IOM said that it is seeking the "full range of perspectives" but did not respond directly to questions about the specifics of how it is going to fulfill that task.

None of the four organizations in California that have an independent perspective on CIRM have been contacted by the IOM, the California Stem Cell Report has been told. They are the state's Little Hoover Commission, the Center for Genetics and Society, Consumer Watchdog and the Citizens Financial Accountability and Oversight Committee, which is the only state body specifically charged with oversight of CIRM and its directors and which is chaired by the state's top fiscal officer, Controller John Chiang. A spokeswoman for the IOM panel said, however, it plans to touch base with at least some of the four.

In response to questions from the California Stem Cell Report, Christine Stencel, the IOM spokeswoman, said the IOM also wants to hear comments from businesses whose applications have been rejected by CIRM. However, she said the panel is still working on "ways to get them." She did not respond directly to questions about how many of such businesses would be interviewed or how they would be selected. The tiny number of CIRM grants to business is a sore spot with industry. Even directors and CIRM's own "external review" panel have said much more is needed.

In response to a question about complaints about conflicts of interest on the part of CIRM reviewers, Stencel was also non-specific, saying only that the panel wants to "obtain all relevant insights." She did not respond directly to a question about whether the panel would examine "private complaints" filed with CIRM by rejected applicants.

Currently the IOM has forms posted online that interested parties, if they know about the existence of the forms, can use to comment on CIRM. We asked whether the panel plans to do more than passively post the forms, specifically whether it plans to email them to all CIRM applicants who were rejected. We also asked about IOM plans to follow up to generate an adequate response. Stencel said the IOM is "proactively working" to get survey responses but did not say what specific steps it was taking.

Our comment?

The IOM has a well-deserved reputation for rigor and thoroughness. However, the IOM is all but unknown to 99 pecent of the public, which will be the ultimate consumer of its findings on the stem cell agency. The fact that the IOM is being paid $700,000 by CIRM will undoubtedly raise questions in the minds of some about IOM's own objectivity. The panel itself consists of persons who have like-minded interests and sympathy with CIRM and its 485 grant recipients. No member of the panel is likely to publicly discourage more scientific research, even if CIRM is deemed to be failing to fulfill the voters expectations in 2004 when they created the agency. All the more reason to aggressively seek out those with contrary views about CIRM's performances, if the IOM's report is to have maximum credibility.

Earlier this week we heard from a knowledgeable and longtime observer of the research scene, who said that the IOM looks at things "differently than regular people" and views scientists who receive funding from CIRM as "independent." The IOM's Stencel responded by reiterating that the IOM is seeking the full range of information from the full range of sources.

The IOM evaluation of CIRM's performance is much too far along not to have progressed further with its attempts to hear from independent and critical voices about CIRM. Generalizations to the effect that "we are going to get to it" do not serve the panel well. The IOM should lay out publicly and quite specifically its plans to aggressively seek thoughtful analysis from parties that do not have financial or professional links to CIRM, as well as from those who feel they have received a short shrift from the $3 billion enterprise.

You can read the full text of the questions from the California Stem Cell Report and the IOM responses here.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

Here is the text of questions from the California Stem Cell Report and answers from the Institute of Medicine concerning its plans to secure independent perspectives during the IOM's examination of the California stem cell agency. So far, the IOM has not heard publicly from any independent sources.

Christine Stencel, a spokeswoman for the IOM, responded for the IOM. She first gave an overall statement. Then she answered the specific queries. We have inserted the questions from the California Stem Cell Report into her text  in order to make the Q&A easier to follow.

The IOM's general comment:

"The committee and staff are planning their next info gathering sessions. Specifics of these events haven't all been worked out yet, but one overall point is that the committee believes it is important to hear the full range of perspectives and experiences with CIRM and the committee members are actively pursuing sources of information that will allow them to adequately answer the questions they've been tasked to explore. The study is ongoing and there are still a lot of people and resources to tap and information to learn.

"To your specific questions:"

California Stem Cell Report:

"Does the IOM have plans to talk with or seek statements from such groups as the Little Hoover Commission and the Center for Genetics and Society or state Controller John Chiang?"

IOM response:

"Yes. And the committee is reading all the past reviews of CIRM."

California Stem Cell Report:

"Does the IOM plan to seek comments from grant applicants rejected by CIRM, particularly businesses? If so how many? How would such applicants be selected by the IOM for interviews or comments?"

IOM response:

"Yes, the committee wishes to hear these perspectives and is seeking ways to get them."

California Stem Cell Report:

"Does the IOM plan to do more than passively post forms for comment from others? Does it plan to email those forms, for example, to all CIRM grant recipients and applicants who were rejected? Does it plan to follow up to be sure an adequate response is generated?"

IOM response:

"The IOM is proactively working to get survey responses and encouraging people to respond."

California Stem Cell Report:

"What does the IOM mean by 'industry partners' on its (online) forms for comment?"

IOM response:

"Industry partners means CIRM investigators representing for-profit companies."

California Stem Cell Report:

"Does the IOM plan to examine both public and private complaints about conflicts of interest on the part of CIRM grant reviewers? By private, I mean written complaints to CIRM that the agency retains but has not made public."

IOM response:

"The committee is looking into the grants review process and working to make sure that the members obtain all relevant insights and information. The committee members intend to invite people who can provide a broad range of experiences with and perspectives of CIRM to the upcoming meeting in April."

The California Stem Cell Report later asked the IOM if it wanted to comment on a quote that we were considering using, which said,

"In the eyes of the IOM, scientists who draw funding from CIRM and other sources are 'independent.' They look at these things differently than regular people would."

The IOM responded,

"As to the quote you sent, as a response we would just reiterate that the committee is methodically going about its task and during the course of the study aims to gather the full range of information, experiences, and insights relevant to CIRM from a full range of sources."

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

The prestigious journal Nature today said that asking California voters for more billions for stem cell research in a few years "may strike residents as a luxury that they can ill afford."

The comment came in a piece by Erika Check Hayden dealing with the future of the California stem cell agency, which is expected to run out of money for new grants in about 2017. She wrote,

"Given that California is facing severe budget shortfalls, several billion dollars more for stem-cell science may strike residents as a luxury that they can ill afford. It may also prove difficult for CIRM’s supporters to point to any treatments that have emerged from the state’s investment. So far, the agency has funded only one clinical trial using embryonic stem cells, and that was halted by its sponsor, Geron of Menlo Park, California, last November.

"Yet the institute has spent just over $1 billion on new buildings and labs, basic research, training and translational research, often for projects that scientists say are crucial and would be difficult to get funded any other way. So the prospect of a future without CIRM is provoking unease. 'It would be a very different landscape if CIRM were not around,' says Howard Chang, a dermatologist and genome scientist at Stanford University in California."

Chang was a scheduled witness recently at a public meeting in California of the blue-ribbon Institute of Medicine panel examining the performance of the Golden State's $3 billion stem cell research effort. Chang is the recipient of $3.2 million in CIRM funding. Hayden wrote,

"Chang has a CIRM grant to examine epigenetics in human embryonic stem cells, and is part of another CIRM-funded team that is preparing a developmental regulatory protein for use as a regenerative therapy. Both projects would be difficult to continue without the agency, he says. Federal funding for research using human embryonic stem cells remains controversial, and could dry up altogether after the next presidential election (see Nature 481, 421–423; 2012). And neither of Chang’s other funders — the US National Institutes of Health (NIH) and the Howard Hughes Medical Institute in Chevy Chase, Maryland — supports his interdisciplinary translational work. Irina Conboy, a stem-cell engineer at the University of California, Berkeley, who draws half of her lab’s funding from CIRM, agrees that in supporting work that has specific clinical goals, the agency occupies a niche that will not easily be filled by basic-research funders. 'The NIH might say that the work does not have a strong theoretical component, so you’re not learning anything new,' she says."

Conboy was also a scheduled witness at the IOM hearing. She holds $2.2 million in CIRM grants.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

A shortage of blood and stem cells in the black community is costing lives, Canada's blood agency warns.

Canadian Blood Services is calling on people of African and Caribbean heritage to register as blood and stem donors through its OneMatch Stem Cell and Marrow Network.

Sickle cell disease is an inherited disease of red blood cells, predominantly affecting people of African descent. In people with sickle cell disease, the red blood cells are abnormally shaped and starve tissues of oxygen.

The lifespan of affected people is about three decades shorter than average, said Dr. Isaac Odame, medical director of the Global Sickle Cell Disease Network at the Hospital for Sick Children in Toronto.

Complications can include infections, extreme bone pain and damage to the brain, lungs, heart and kidneys, Odame said.

Kynan Jackson, 7, of Halifax struggles with painful sickle cell disease. He takes medication twice a day, has had blood transfusions and been admitted to the hospital a few times since he was diagnosed at age four.

"It is stressful," said his mother, Winnell Jackson. "It's almost like a waiting game. The medication won't ever stop him from getting crisis again, so I know it's coming."

A stem cell transplant replaces the bad, misshapen ones with normal ones, said Odame.

"The only way to give him [Kynan] a chance is to cure it," Odame said. "We know that it can be cured through stem cell transplantation."

Stem cell transplants require a close match from a donor of the same ethnic background, which narrows Kynan's odds of getting one.

"If you are Caucasian and you're looking for an unrelated match, probably 75 per cent chance you will find one. If you are of African descent, your odds are far, far, far less," Odame said.

Canada's blacks represent about 2.5 per cent of the population, based on the 2006 census. But of the 300,000 on the blood agency's stem cell and marrow registry, only 0.7 per cent are of African descent.

"Sometimes people wait six months to years to find a match and they may end up passing away in that time period because we can't find a match in Canada or around the world," said Sue Smith, executive director of One Match.

During Black History Month, Canadian Blood Services is appealing for young, black male donors in particular to donate blood and be registered. Men tend to be bigger and deliver a larger volume of stem cells without the complications of an over-reactive immune system that can occur during pregnancy.

Currently, the agency said there is a waiting list of 36 African Canadians with cancer who could be cured with a stem cell transplant. Kynan's mom hopes the campaign is a success and she's able to see him grow up.

It would "be really nice to know that, you know what, he does have a match out there. There's somebody out there wherever they may be, that would match him and be able to take that pain, help ease that pain in his life."

The blood agency's theme this year, "Our Canadian Story: Making Community Engagement a Priority," emphasizes community.

Read the original here:
Blacks urged to donate blood, stem cells

02-09-2011 03:47 metromd.net Stem Cells to Treat Acne Scarring | An overview by Alex Martin, MD of how he combines stem cell therapy and the CO2 fractional laser to effectively treat facial scars caused by acne. Offices near Hollywood, Beverly Hills, Los Angeles and Orange County. Questions? Please call the MetroMD Institute of Regenerative Medicine at (323) 285-5300 or email us at info@MetroMD.net.

Read this article:
Stem Cells to Treat Acne Scarring | Los Angeles | Hollywood | Beverly Hills - Video

01-02-2012 21:36 Notes from the interview: Nicholas Anderson - Author, NOC: British Secret Operations Big Pharma... must be careful in discussing reason for writing books is in part because of something along these lines medical doctor helped to exfiltrate from soviet union end of 1991 doctor wanted to meet... nicholas anderson flew to meet in moscow... bottom line: he claimed to have number of effective treatments and cures... MIND YOU... he's not trying to get your hopes up, but you should look into alternate treatments natural remedies. stem cell, energetic medicine is more detail in the book? when the book was written, it was non-fiction. but it didn't last to be a non-fiction novel. former secret operations must be cleared. large majority that was redacted or cleared from the fiction novel was about big pharma. certain things -are- in the book. also know that nicholas anderson was skeptical about these items first. even so, he wondered why aren't these alternative cures more widely known? the doctor appeared on a primetime show and the media prevented him from saying what he wanted to say... in a couple examples, they removed things he had said. they said the -opposite- of what he actually said. it was then that he realized he was on to something and he saw that happening. did this doctor have access to this medicine in the soviet union or was it secretive? in the beginning of communism, they did come up with things in medicine that the west never did come up with. this doctor had ...

Read more from the original source:
NOC Interview 2: Big Pharma - Video